Keros Therapeutics, Inc. (KROS)
Develops experimental drugs to treat muscle-wasting and blood disorders by blocking harmful protein signals.
$9.96-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-30.4%
The outlook
KROS is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a downtrend. The overall analyst lean is bearish, though the average price target sits roughly 119% above the current price, suggesting a wide gap between current sentiment and longer-term expectations. The stock remains thinly valued relative to analyst upside views.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +119% vs current price
Analyst price target
~12-month · 6 analysts$21.83average target+119.2% vs now
Now $9.96
Low $16.00High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$197.1M
52-wk high
$22.55
52-wk low
$9.69
50-day avg
$10.73
200-day avg
$14.37
Trailing P/E
—